Rebound Phenomenon after Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease-2019 in High-Risk Persons.

Nischal RanganathJohn C O'HoroDouglas W ChallenerSidna M Tulledge-ScheitelMarsha L PikeR Michael O'BrienRaymund R Razonable Aditya S Shah

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)

In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for coronavirus disease-2019, two patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at median of 9 days after treatment, and all resolved without additional COVID-19-directed therapy.

Keyphrases

coronavirus disease
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
sars cov
respiratory syndrome coronavirus
depressive symptoms